Insilico Medicine develops new AI-generated FGFR2/3 inhibitor for tissue-agnostic solid tumors

Insilico Medicine (“Insilico”), a generative artificial intelligence (AI)-driven clinical-stage drug discovery company, today announced the nomination of ISM8001, a novel molecule targeting FGFR2/3 for the treatment of tissue-agnostic solid tumors bringing the total number of PCCs nominated in 2023 to six.

NIH study reveals elevated cholesterol levels among American Indian youth

More than 70% of American Indian young adults aged 20-39 and 50% of American Indian teens have cholesterol levels or elevated fat in the blood

March 6, 2024

CKMT2 regulates mitochondrial function and energy metabolism in type 2 diabetes

Creatine kinase M2 (CKMT2) plays a key role in mitochondrial dysfunction in type 2 diabetes, affecting energy metabolism in skeletal muscle.

October 10, 2024

Sustained Disease Control in Adolescent Myasthenia Gravis With FcRn Blocker

SAVANNAH, Ga. — Investigational nipocalimab plus standard of care achieved sustained reductions in immunoglobulin G (IgG) and appeared to be safe for adolescent patients with

October 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.